EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluating the Effectiveness of Nirsevimab in Reducing Pediatric RSV Hospitalizations in Spain

Sara Jimeno Ruiz iD, Adrián Peláez iD, Agustín Labourt, Florencia Mercedes Acuña, Lucía Linares, Isabel Llana Martín, Ángeles Calle Gómez, Silvina Natalini Martínez iD

Vaccines · 11.10.2024 · 12 (10) · 1160

DOI: 10.3390/vaccines12101160 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vaccines, online erschienen am 11.10.2024. Verfasst von Sara Jimeno Ruiz und 7 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Pediatría, Hospital HM Puerta del Sur, HM Hospitales, 28938 Madrid, Spain. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Respiratory syncytial virus (RSV) is a major cause of hospitalization in infants. Nirsevimab has demonstrated to be a promising tool for preventing severe RSV disease. Although clinical trials have demonstrated the efficacy of Nirsevimab in preventing severe RSV disease, evidence regarding its performance in real-world clinical settings is still limited due to its recent introduction. This study aims to fill this knowledge gap by evaluating the impact of Nirsevimab in a cohort of infants and determining its effectiveness in reducing the burden of RSV disease.

Methods

A retrospective study of RSV hospitalizations was conducted in children under six months of age, between 1 October and 31 March, across four seasons: pre-COVID (2018–2019), COVID (2019–2020), post-COVID pre-Nirsevimab (2022–2023), and Nirsevimab season (2023–2024).

Results

Nirsevimab demonstrated significant efficacy in reducing RSV-related hospitalizations in infants under six months of age. During the 2023/2024 season, following the introduction of Nirsevimab, there was a substantial reduction in RSV-related lower respiratory tract infection (LRTI) hospitalizations. Among infants under 3 months of age, hospitalizations decreased by 79.3% (IRR: 0.21, 95% CI: 0.12–0.34). In infants aged 3 to 6 months, there was a 66.9% reduction (IRR: 0.33, 95% CI: 0.15–0.64). Additionally, Nirsevimab decreased the severity of RSV cases with LRTI who required the support of equipment for sanitary use, further reducing overall healthcare burden.

Conclusions

These results underscore Nirsevimab’s vital role in preventing severe RSV infections and hospitalizations, especially among the most vulnerable infants, positioning it as a critical advancement in pediatric respiratory care.

Schlagwörter

Stichwörter der Autor:innen

NirsevimabRSV-related lower respiratory tract infectionhealthcare burden reductionpediatric respiratory carerespiratory syncytial virus (RSV)

Autor:innen und Institutionen

  • Departamento de Pediatría, Hospital HM Puerta del Sur, HM Hospitales, 28938 Madrid, Spain.
  • Unidad de Vacunas, HM Hospitales, 28938 Madrid, Spain.
  • Facultad de Ciencias de la Salud-HM Hospitales, Universidad Camilo José Cela, 28692 Madrid, Spain.
  • Instituto de Investigación Sanitaria HM Hospitales, 28015 Madrid, Spain.
  • Departamento de Unidad de Análisis de Datos, Fundación de Investigación HM Hospitales, Facultad de Ciencias de la Salud-HM Hospitales, Universidad Camilo José Cela, 28692 Madrid, Spain.
  • Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain.

ORCID-Profile: Sara Jimeno Ruiz, Adrián Peláez, Silvina Natalini Martínez

Zitieren

APA

Jimeno Ruiz, S., Peláez, A., Labourt, A., Acuña, F. M., Linares, L., Llana Martín, I., Calle Gómez, Á., & Martínez, S. N. (2024). Evaluating the Effectiveness of Nirsevimab in Reducing Pediatric RSV Hospitalizations in Spain. Vaccines, 12(10), 1160. https://doi.org/10.3390/vaccines12101160

Vancouver

Jimeno Ruiz S, Peláez A, Labourt A, Acuña FM, Linares L, Llana Martín I, et al. Evaluating the Effectiveness of Nirsevimab in Reducing Pediatric RSV Hospitalizations in Spain. Vaccines. 2024;12(10):1160. doi:10.3390/vaccines12101160

BibTeX
@article{JimenoRuiz2024,
  author = {Jimeno Ruiz, Sara and Peláez, Adrián and Labourt, Agustín and Acuña, Florencia Mercedes and Linares, Lucía and Llana Martín, Isabel and Calle Gómez, Ángeles and Martínez, Silvina Natalini},
  title = {Evaluating the Effectiveness of Nirsevimab in Reducing Pediatric RSV Hospitalizations in Spain},
  journal = {Vaccines},
  year = {2024},
  volume = {12},
  number = {10},
  pages = {1160},
  doi = {10.3390/vaccines12101160}
}
Kostenlos starten →